ET-2/Endothelin 2 Polyclonal Antibody, APC-Cy7 Conjugated
Cat# bs-11280R-APC-Cy7
Size : 100ul
Brand : Bioss
Contact local distributor :
Phone : +1 850 650 7790
ET-2/Endothelin 2 Polyclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-11280R-APC-Cy7 |
| Product Name | ET-2/Endothelin 2 Polyclonal Antibody, APC-Cy7 Conjugated |
| Applications | IF(IHC-P), IF(IHC-F), IF(ICC) |
| Reactivity | Cat |
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Cat, Rabbit |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Endolin 2 |
| Immunogen Range | 49-59/178 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Secreted |
| Synonyms | EDN2; EDN2_HUMAN; Endothelin 2; Endothelin-2; ET 2; ET-2; ET2; PPET2; Preproendothelin 2; Preproendothelin-2. |
| Background | The endothelin (ET) family of proteins, which includes ET-1 (endothelin-1), ET-2 (endothelin-2) and ET-3 (endothelin-3), are vasoactive peptides that are involved in various functions throughout the body. Endothelins can affect the central nervous system and neuronal excitability, and they elicit potent vasoconstrictor action. While ET-1 is a potent, 21-amino acid vasoconstrictor peptide, ET-2 has the most potent vasoconstrictor activity. ET-3 functions as a ligand for endothelin receptor type B (ETBR) and, through this interaction, mediates the maturation of enteric neurons and melanocytes. Although ET-3 is expressed as a 238 amino acid peptide, it is post-translationally modified to produce a short active isoform and a long inactive isoform. Defects in the gene encoding ET-3 are the cause of a variety of disorders, including Hirschsprung disease type 1 (HSCR1), congenital central hypoventilation syndrome (CCHS) and Waardenburg syndrome type IV (WS4). |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |